转移性乳腺癌的新型靶向治疗方法。
Novel targeted therapies for metastatic breast cancer.
作者信息
Jazieh Khalid, Bell Ruth, Agarwal Nayan, Abraham Jame
机构信息
Department of Internal Medicine, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
出版信息
Ann Transl Med. 2020 Jul;8(14):907. doi: 10.21037/atm.2020.03.43.
Abstract
Metastatic breast cancer (mBC) continues to be a leading cause of cancer-related death in women. Even though mortality rates have improved over recent years, the 5-year survival rate of advanced BC is still at only 27%. As researchers and clinicians attempt to tackle this challenge, there has been extensive research and many trials studying treatment options for BC patients with metastatic disease, with numerous new therapies being discovered as a result. We review the most pertinent novel agents to enter the scope of BC treatment, including CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, immunotherapy, PARP inhibitors, and more.
摘要
转移性乳腺癌（mBC）仍然是女性癌症相关死亡的主要原因。尽管近年来死亡率有所改善，但晚期乳腺癌的5年生存率仍仅为27%。随着研究人员和临床医生试图应对这一挑战，针对转移性疾病的乳腺癌患者的治疗选择进行了广泛的研究和许多试验，结果发现了许多新疗法。我们回顾了进入乳腺癌治疗范围的最相关新型药物，包括细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂、磷脂酰肌醇-3激酶（PI3K）抑制剂、哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂、免疫疗法、聚（ADP-核糖）聚合酶（PARP）抑制剂等。
相似文献
1
Novel targeted therapies for metastatic breast cancer.转移性乳腺癌的新型靶向治疗方法。
Ann Transl Med. 2020 Jul;8(14):907. doi: 10.21037/atm.2020.03.43.
2
Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.转移性乳腺癌患者接受 PI3K/mTOR/CDK4/6 抑制剂治疗后的外周水肿发生率。
Breast Cancer Res Treat. 2019 Jun;175(3):649-658. doi: 10.1007/s10549-019-05206-y. Epub 2019 Mar 27.
3
Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.细胞周期蛋白依赖性激酶4/6（CDK4/6）和磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白（PI3K/AKT/mTOR）抑制剂治疗激素受体阳性、人表皮生长因子受体2（HER2）阴性转移性乳腺癌女性患者的疗效和安全性比较：一项系统评价和网状Meta分析
Curr Probl Cancer. 2020 Dec;44(6):100606. doi: 10.1016/j.currproblcancer.2020.100606. Epub 2020 May 12.
4
CDK4/6 inhibitors in breast cancer - from models to clinical trials.CDK4/6 抑制剂在乳腺癌中的应用：从模型到临床试验。
Acta Oncol. 2020 Feb;59(2):219-232. doi: 10.1080/0284186X.2019.1684559. Epub 2019 Oct 31.
5
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
6
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.PI3K-AKT-mTOR 抑制剂在乳腺癌中的作用：从肿瘤细胞信号转导到临床试验。
Pharmacol Ther. 2017 Jul;175:91-106. doi: 10.1016/j.pharmthera.2017.02.037. Epub 2017 Feb 16.
7
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.黑色素瘤研究的未来展望：“黑色素瘤桥梁”会议报告：那不勒斯，2014年12月3日至6日
J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.
8
Therapeutics targeting the metastatic breast cancer bone microenvironment.针对转移性乳腺癌骨微环境的治疗方法。
Pharmacol Ther. 2022 Nov;239:108280. doi: 10.1016/j.pharmthera.2022.108280. Epub 2022 Sep 16.
9
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.乳腺癌中 CDK4/6 抑制剂策略及联合治疗的最新进展。
Cells. 2019 Apr 6;8(4):321. doi: 10.3390/cells8040321.
10
Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.HER2阳性乳腺癌中酪氨酸激酶抑制剂的临床进展
Front Pharmacol. 2022 Dec 12;13:1089066. doi: 10.3389/fphar.2022.1089066. eCollection 2022.
引用本文的文献
1
Novel Thymoquinone Derivative TQFL28 Inhibits Triple-Negative Breast Cancer (TNBC) Invasiveness In Vitro and In Vivo.新型百里醌衍生物TQFL28在体内外均能抑制三阴性乳腺癌（TNBC）的侵袭性。
Curr Issues Mol Biol. 2025 Jun 1;47(6):412. doi: 10.3390/cimb47060412.
2
A retrospective cohort study to evaluate disease burden, health care resource utilization, and costs in patients with breast cancer in Dubai, UAE.一项回顾性队列研究，评估了阿联酋迪拜的乳腺癌患者的疾病负担、医疗资源利用情况和成本。
BMC Health Serv Res. 2024 Jul 12;24(1):810. doi: 10.1186/s12913-024-11193-8.
3
Therapeutic Approaches to Increase the Survival Rate of Cancer Patients in the Younger and Older Population.提高年轻和老年癌症患者生存率的治疗方法。
Curr Aging Sci. 2024;17(1):16-30. doi: 10.2174/0118746098241507231127114248.
4
Design, Synthesis, and Acute Toxicity Assays for Novel Thymoquinone Derivative TQFL12 in Mice and the Mechanism of Resistance to Toxicity.新型百里醌衍生物 TQFL12 的设计、合成及在小鼠体内的急性毒性试验及耐药机制研究。
Molecules. 2023 Jun 30;28(13):5149. doi: 10.3390/molecules28135149.
5
Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein.自分化髓样来源树突状细胞激活细胞毒性 T 淋巴细胞杀伤表达叶酸受体α蛋白的乳腺癌细胞。
Bioengineered. 2022 Jun;13(6):14188-14203. doi: 10.1080/21655979.2022.2084262.
6
'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.通过综合多组学技术实现乳腺癌耐药可能性及个性化治疗
Front Mol Biosci. 2022 Apr 14;9:783494. doi: 10.3389/fmolb.2022.783494. eCollection 2022.
7
Identification of m6A-Associated Gene DST as a Prognostic and Immune-Associated Biomarker in Breast Cancer Patients.鉴定m6A相关基因DST作为乳腺癌患者的预后和免疫相关生物标志物
Int J Gen Med. 2022 Jan 12;15:523-534. doi: 10.2147/IJGM.S344146. eCollection 2022.
8
miR-4759 suppresses breast cancer through immune checkpoint blockade.微小RNA-4759通过免疫检查点阻断抑制乳腺癌。
Comput Struct Biotechnol J. 2021 Dec 16;20:241-251. doi: 10.1016/j.csbj.2021.12.020. eCollection 2022.
9
A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics.关于FoxM1在乳腺癌发生发展及治疗中的研究进展的叙述性综述。
Ann Transl Med. 2021 Nov;9(22):1704. doi: 10.21037/atm-21-5271.
10
TQFL12, a novel synthetic derivative of TQ, inhibits triple-negative breast cancer metastasis and invasion through activating AMPK/ACC pathway.TQFL12，TQ 的一种新型合成衍生物，通过激活 AMPK/ACC 通路抑制三阴性乳腺癌转移和侵袭。
J Cell Mol Med. 2021 Nov;25(21):10101-10110. doi: 10.1111/jcmm.16945. Epub 2021 Oct 5.
本文引用的文献
1
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.FDA 批准概要：fam-trastuzumab deruxtecan-nxki 用于治疗不可切除或转移性 HER2 阳性乳腺癌。
Clin Cancer Res. 2021 Aug 15;27(16):4478-4485. doi: 10.1158/1078-0432.CCR-20-4557. Epub 2021 Mar 22.
2
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.曲妥珠单抗、曲妥珠单抗和卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11.
3
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
4
Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.三种酪氨酸激酶抑制剂拉帕替尼、奈拉替尼和吡咯替尼在HER2阳性乳腺癌中的作用机制、安全性及疗效
Am J Cancer Res. 2019 Oct 1;9(10):2103-2119. eCollection 2019.
5
Lucitanib for the Treatment of HR/HER2 Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.卢西替尼治疗 HR/HER2 转移性乳腺癌：来自多队列 II 期 FINESSE 研究的结果。
Clin Cancer Res. 2020 Jan 15;26(2):354-363. doi: 10.1158/1078-0432.CCR-19-1164. Epub 2019 Oct 16.
6
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.阿贝西利联合氟维司群治疗激素受体阳性、HER2 阴性乳腺癌的疗效：内分泌治疗进展后总生存的影响——MONARCH 2 随机临床试验
JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782.
7
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.T-DM1 联合奈拉替尼治疗转移性 HER2 阳性乳腺癌患者的安全性和疗效：NSABP 基金会试验 FB-10。
J Clin Oncol. 2019 Oct 10;37(29):2601-2609. doi: 10.1200/JCO.19.00858. Epub 2019 Aug 23.
8
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.瑞博西利联合内分泌治疗乳腺癌的总生存。
N Engl J Med. 2019 Jul 25;381(4):307-316. doi: 10.1056/NEJMoa1903765. Epub 2019 Jun 4.
9
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.阿培利司治疗 - 突变型、激素受体阳性晚期乳腺癌。
N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.
10
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.转移性三阴性乳腺癌的免疫诱导策略，以提高对 PD-1 阻断的敏感性：TONIC 试验。
Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13.
Zotero 插件